Productive and Inclusive Cities for an Emerging Democratic Republic of Congo
Представлены данные о факторах риска, которые способствуют развитию суицидального поведения. На развитие суицидального поведения влияет целый ряд факторов: пол, ...озраст, место проживания, профессия, семейное положение, состояние здоровья и т.д. Отмечается влияние экономических и социальных факторов на уровень суицидальной активности населения. Наблюдаются взаимосвязи между психическими расстройствами, наркологическими заболеваниями (особенно алкоголизм) и суицидом. При наличии многочисленных исследований в области суицидологии целый ряд проблем остаётся неразрешенным. Необходимо их дальнейшее изучение. Особо следует отметить значимость «региональных» факторов риска, которые оказывают наибольшее влияние на формирование суицидального поведения в отдельно взятом регионе.
more
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more
Le Plan Stratégique National de Lutte contre le Paludisme 2023–2026 du Togo définit les grandes orientations pour réduire de 65 % l’incidence et la mortalité liées au paludisme d’ici 2026, en comparaison avec les niveaux de 2022. Élaboré par le Programme National de Lutte contre le Pa...ludisme (PNLP), il s’inscrit pleinement dans les objectifs mondiaux fixés par l’Organisation mondiale de la Santé pour parvenir à l’élimination du paludisme d’ici 2030. Ce plan repose sur quatre axes stratégiques : la prévention à travers l’utilisation des moustiquaires imprégnées, la chimio-prévention et la lutte antivectorielle ; la prise en charge efficace des cas grâce au diagnostic rapide et au traitement par ACT ; le renforcement du système de santé et la gestion du programme ; ainsi que la surveillance, le suivi et l’évaluation des interventions. Une attention particulière est accordée à la digitalisation des outils, à l’amélioration de la qualité des données, à l’implication des communautés locales et à la réduction des inégalités régionales dans l’accès aux services. Intégrant les partenaires techniques et financiers, le secteur privé et les acteurs communautaires, ce document constitue une véritable feuille de route nationale pour coordonner et intensifier la lutte contre le paludisme sur la période 2023–2026.
more
Data Collection: Recommended Surgical and Anaesthesia Care Indicators
Volume 2 · Supplement 4 · November 2016
ISSN 2055-66-40 – Print
Foreword
| ISSN 2055-66-59 – Online
www.viruseradication.com
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
Overview:
- Part A is an introductory part which will give you background information about CBDRR in Myanmar. It has a small section about the importance of CBDRR in Myanmar, the stakeholders of CBDRR in Myanmar, as well as an overview about the challenges that are faced when implementing CBDRR... in Myanmar.
- Part B contains the instructions on how to conduct the 9-step process agreed upon and described in detail in the step-by-step methodology document. These nine (9) steps are considered the minimum required activities to be followed by all MRCS community based initiatives regardless of their budget or time frame.
- Part C includes all the implementation steps of CBDRR programs namely step 6 (Action Plan Development), and step 7 (Implementation of Action Plan).
- Part D includes all the steps that finalize a CBDRR program namely step 4 and step 8 (Baseline and Endline Study) as well as step 9 (Handover & Exit Strategy).
more
A guide for developing a hygiene promotion program to increase handwashing with soap
Since the start of the pandemic, the region has been hit by multiple natural and biological disasters. At the same time, climate change has continued to warm the world, exacerbating the impacts of many of these disasters. The *Asia-Pacific Disaster Report 2021, *also launched today, shows that the p...andemic, combined with the persistent reality of climate change, has reshaped and expanded the disaster “riskscape” in Asia and the Pacific.
more